Aesica Pharmaceuticals Limited - Strategic SWOT Analysis Review

Introduction

Aesica Pharmaceuticals Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.

- Corporate strategy – GlobalData’s summarization of the company’s business strategy.

- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.

- Company history – Progression of key events associated with the company.

- Major products and services – A list of major products, services and brands of the company.

- Key competitors – A list of key competitors to the company.

- Key employees – A list of the key executives of the company.

- Executive biographies – A brief summary of the executives’ employment history.

- Key operational heads – A list of personnel heading key departments/functions.

- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

- Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

Aesica Pharmaceuticals Limited (Aesica) is a contract development and manufacturing organization (CDMO). It manufactures active pharmaceutical ingredients (APIs) and finished dosage forms. The company’s services include pre-formulation, formulation and manufacturing services, analysis and stability testing, manufacture of clinical trial materials, regulatory support and technology transfer. It classifies offerings into three divisions, namely, Active Pharmaceutical Ingredients (APIs), Formulation Development, and Finished Products. The company operates manufacturing facilities in the UK, Germany and Italy. It is a subsidiary of Consort Medical plc. Aesica is headquartered in Newcastle upon Tyne, the UK.

The company focuses on becoming a leading supplier of active pharmaceutical ingredients and formulated products to the pharmaceutical industry.

Aesica Pharmaceuticals Limited Key Recent Developments

Oct 14, 2015: Aesica introduces new service model with one CDMO managing a customer’s entire supply chain

Oct 08, 2015: Aesica launches new brand identity to the market

Sep 24, 2015: Development Portfolio: S+flurbiprofen

Sep 14, 2015: Development Portfolio: Semi-Continuous Manufacturing

Feb 02, 2015: Aesica secures continuing FDA approval of its bulk manufacture and packaging sites in Germany

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.

- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.

- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.

- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Table of Contents
for Aesica Pharmaceuticals Limited - Strategic SWOT Analysis Review

• Table of Contents

  Table of Contents 2

  List of Tables 4

  List of Figures 5

  Section 1 - About the Company 6

  Aesica Pharmaceuticals Limited - Key Facts 6

  Aesica Pharmaceuticals Limited - Key Employees 7

  Aesica Pharmaceuticals Limited - Key Employee Biographies 8

  Aesica Pharmaceuticals Limited - Key Operational Employees 9

  Aesica Pharmaceuticals Limited - Major Products and Services 10

  Aesica Pharmaceuticals Limited - History 11

  Aesica Pharmaceuticals Limited - Company Statement 14

  Aesica Pharmaceuticals Limited - Locations And Subsidiaries 15

  Head Office 15

  Other Locations & Subsidiaries 15

  Section 2 – Company Analysis 17

  Aesica Pharmaceuticals Limited - Business Description 17

  Aesica Pharmaceuticals Limited - Corporate Strategy 18

  Aesica Pharmaceuticals Limited - SWOT Analysis 19

  SWOT Analysis - Overview 19

  Aesica Pharmaceuticals Limited - Strengths 19

  Strength - Broad Range of Solutions 19

  Strength - Manufacturing Capabilities 19

  Strength - Synergy with Parent 19

  Aesica Pharmaceuticals Limited - Weaknesses 20

  Weakness - Penalties 20

  Aesica Pharmaceuticals Limited - Opportunities 21

  Opportunity - Expansion Initiatives 21

  Opportunity - Strategic Agreement 21

  Opportunity - Market Potential: Outsourcing Business 21

  Aesica Pharmaceuticals Limited - Threats 22

  Threat - Government Regulations 22

  Threat - Industry Consolidation 22

  Threat - Tough Competitive Market 22

  Aesica Pharmaceuticals Limited - Key Competitors 23

  Section 3 – Company’s Lifesciences Financial Deals and Alliances 24

  Aesica Pharmaceuticals Limited, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 24

  Aesica Pharmaceuticals Limited, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 25

  Aesica Pharmaceuticals Limited, Recent Deals Summary 26

  Section 4 – Company’s Recent Developments 27

  Oct 14, 2015: Aesica introduces new service model with one CDMO managing a customer’s entire supply chain 27

  Oct 08, 2015: Aesica launches new brand identity to the market 28

  Sep 24, 2015: Development Portfolio: S+flurbiprofen 29

  Sep 14, 2015: Development Portfolio: Semi-Continuous Manufacturing 30

  Feb 02, 2015: Aesica secures continuing FDA approval of its bulk manufacture and packaging sites in Germany 31

  Oct 08, 2014: Aesica provides a full high potent service – drug development through to commercial covering both API and drug product manufacturing 32

  Oct 07, 2014: Aesica provides a full controlled drugs service from development through to commercial scale supply – handling both API and drug product manufacturing of scheduled drugs 33

  Aug 19, 2014: Aesica appoints new product release manager 34

  Jul 02, 2014: Aesica recruits new Business Development Manager to aid sales drive across German, Austrian and Swiss Markets 35

  Jun 23, 2014: Aesica Pharmaceuticals S.r.I. collaborates with QAD to meet China’s Food and Drug Administration’s shortened serialisation deadline 36

  Section 5 – Appendix 37

  Methodology 37

  About GlobalData 37

  Contact Us 37

  Disclaimer 37

List Of Tables
in Aesica Pharmaceuticals Limited - Strategic SWOT Analysis Review

List of Tables

Aesica Pharmaceuticals Limited, Key Facts 6

Aesica Pharmaceuticals Limited, Key Employees 7

Aesica Pharmaceuticals Limited, Key Employee Biographies 8

Aesica Pharmaceuticals Limited, Key Operational Employees 9

Aesica Pharmaceuticals Limited, Major Products and Services 10

Aesica Pharmaceuticals Limited, History 11

Aesica Pharmaceuticals Limited, Other Locations 15

Aesica Pharmaceuticals Limited, Subsidiaries 15

Aesica Pharmaceuticals Limited, Key Competitors 23

Aesica Pharmaceuticals Limited, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 24

Aesica Pharmaceuticals Limited, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 25

Aesica Pharmaceuticals Limited, Recent Deals Summary 26

List Of Figures, Charts and Diagrams
in Aesica Pharmaceuticals Limited - Strategic SWOT Analysis Review

List of Figures

Aesica Pharmaceuticals Limited, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 24

Aesica Pharmaceuticals Limited, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 25

Additional Details

Publisher

Global Data

Publisher Information

Reference

706 | GDPH133985SA

Number of Pages

37

Report Format

PDF

Related Reports